docMelanoma - Global Drug Forecast and Market worth 5.64 Billion USD by 2023
download 
Report Transcription
Melanoma - Global Drug Forecast and Market worth 5.64 Billion USD by 2023 Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. It is estimated the 2013 sales for melanoma at approximately $1.34 billion across the 8MM covered in the Mentioned in Melanoma - Global Drug Forecast and Market Analysis Report. This report, " Melanoma - Global Drug Forecast and Market Analysis to 2023" focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for melanoma. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Melanoma - Global Drug Forecast and Market Analysis Report at – http://www.absolutereports.com/pharmapoint-melanomaglobal-drug-forecast-and-market-analysis-to-2023-10076082 The market will increase by four-fold over the forecast period, reaching $5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma incident cases as well as the approval and uptake of premium-priced products, such as PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. Ask for Discount on Melanoma - Global Drug Forecast and Market Analysis Report at – http://www.absolutereports.com/enquiry/request-discount/10076082 The melanoma pipeline is strong; however, none of these drugs to have a major impact on the overall melanoma market, as the market is crowded with effective immunotherapies and BRAF mutationtargeted agents. The challenge for new entrants into the melanoma market is to find patient populations that are currently underserved. One of the opportunities for the companies is to work cooperatively to develop novel combinations of immuno/targeted-therapies. Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10076082 One of the main drivers of the enormous expansion of the gout market will be the launch of premiumpriced metastatic therapies, such as anti-PD-1 immunotherapy and BRAF/MEK inhibitor combinations. +1 408 520 9750 www.absolutereports.com These drugs will extend treatment duration and replace cheaper, generic, chemotherapy regimens. - Another strong driver will be the label extension of current therapies into the new settings; for example, PD-1s will garner label extension for the first-line treatment in 2015-16, and the metastatic brands are expected to be approved in the adjuvant setting in the second half of the forecast period. About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact– Mr. Ameya Pingaley Absolute Reports +1-408 520 9750 Email – [email protected] Website: www.absolutereports.com +1 408 520 9750 www.absolutereports.com
Similar documents
Medtronic plc, Bioventus LLC and Depuy Companies Dominate the UK Orthobiologics Market Report
The orthobiologics market in the UK is expected to be driven by patient demographics, the development of novel product designs, increasing patient awareness, increasing participation in sports related activities, and a rising incidence of road accidents. The data in the report is derived from dynamic market forecast models.
France Orthopedic Prosthetics Procedure report to 2021, Market Shares, Research Report, Industry Analysis, Forecast Opportunity
prosthesis is a functional replacement for an amputated or congenitally malformed or missing limb. Prosthetists are responsible for the prescription, design and management of a prosthetic device. In most cases, the prosthetist begins by taking a plaster cast of the patient's affected limb. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market segments - Lower Extremity Prosthetics and Upper Extremity Prosthetics.
Ventricular Fibrillation: Global Industry Analysis, Trends, Market Demands, Segment and Forecast
Ventricular Fibrillation- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India.
Latest Research Report on Medical Equipment Monthly Deals Analysis: JANUARY 2016 - M&A and Investment Trends
Medical Equipment Monthly Deals Analysis: JANUARY 2016 report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in January 2016.
